ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±ÂÞ¶¬ÁᣩÒûʳÒòËØÓëÈËÀ࿵½¡Ç×½üÏà¹Ø¡£¡£½üÄêÀ´·¢Ã÷£¬£¬À±½·ÉãÈë¾ßÓжàÖÖÐÄѪ¹Ü»ñÒæ£¬£¬Í¨ÀýÉãÈëÀ±½·ÓÐÖúÓÚ½µµÍÐÄѪ¹Ü¼²²¡µÄéæÃü·çÏÕ¡£¡£×÷ΪÐÄѪ¹Ü¼²²¡µÄÖ÷ҪΣÏÕÒòËØ£¬£¬Ñª¹Ü¸Æ»¯ÓëÀ±½·ÉãÈëµÄ¹ØÏµÉв»Ã÷È·¡£¡£
3ÔÂ2ÈÕ£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚ°ËÒ½Ôº»Æ»Ô½ÌÊÚÍŶÓÔÚHypertension£¨IF 10.19£©½ÒÏþÁËÌâΪ¡°Capsaicin Attenuates Arterial Calcification Through Promoting SIRT6-Mediated Deacetylation and Degradation of Hif1¦Á (Hypoxic-Inducible Factor-1 Alpha)¡±µÄÎÄÕ£¬£¬Ê×´ÎÌá³öÀ±½·ÉãÈë¶ÔѪ¹Ü¸Æ»¯µÄÔ¤·À±£»£»¤×÷Ó㬣¬ÎªÖÎÁÆÑª¹Ü¸Æ»¯ÌṩÁËÐÂ˼Ð÷¡£¡£
ÔÚ¸ÃÑо¿ÖУ¬£¬×÷Õß·¢Ã÷£¬£¬À±½·ÉãÈëÕߵĹÚÂö¸Æ»¯»ý·ÖÏÔÖøµÍÓÚ·ÇÉãÈëÕß¡£¡£²¢ÇÒÀ±½·ÉãÈëÕßÔÚËæ·ÃÀú³ÌÖÐÕ¹ÏÖ³ö¸üÉٸƻ¯Ï£Íû¼ç¸º¡£¡£Ëæ×ÅÀ±½·ÉãÈëÁ¿µÄÔöÌí£¬£¬Ñª¹Ü¸Æ»¯»ý·ÖˮƽÖð½¥½µµÍ¡£¡£Í¬Ê±¶¯ÎPϸ°ûʵÑéÖнøÒ»²½Õ¹ÏÖÀ±½·ËضÔѪ¹Ü¸Æ»¯µÄ±£»£»¤×÷ÓúͻúÖÆ¡£¡£Ôڸƻ¯Ä£×ÓÖУ¬£¬SIRT6±í´ïïÔÌ£¬£¬È±ÑõÓÕµ¼Òò×ÓHif1¦ÁÎȹÌÐÔÔöÌí£¬£¬µ¼ÖÂѪ¹Üƽ»¬¼¡Ï¸°ûÏò³É¹Ç±íÐÍת»¯¡£¡£¶øÀ±½·ÉãÈë¿É¼¤»î1ÐÍ˲ʱ¸ÐÊÜÆ÷µçλÏã²ÝËØ£¨transient receptor potential vanilloid type 1£¬£¬TRPV1£©£¬£¬½ø¶øÉϵ÷SIRT6£¬£¬Ôö½øHif1¦ÁÈ¥ÒÒõ£»£»¯¼°½µ½â£¬£¬ÒÖÖÆÑª¹Üƽ»¬¼¡Ï¸°û³É¹Ç±íÐÍת»¯£¬£¬Ê©Õ¹Ñª¹Ü¸Æ»¯µÄ±£»£»¤×÷Óᣡ£

Ѫ¹Ü¸Æ»¯ÊÇÐÄÄÔѪ¹Ü¼²²¡¸ß·¢²¡Âʼ°¸ßéæÃüÂʵÄÖ÷ҪΣÏÕÒòËØ£¬£¬µ«ÓÉÓÚÆä±¬·¢ÆøÖÆÖش󣬣¬ÏÖÔÚÉÐÎÞÓÐÓõÄÖÎÁÆÊֶΡ£¡£¶øÔÚ±¾Ñо¿ÖУ¬£¬»Æ»Ô½ÌÊÚÍŶӷ¢Ã÷£¬£¬À±½·ËØ¿ÉÒÖÖÆÑª¹Üƽ»¬¼¡Ï¸°û³É¹Ç±íÐÍת»¯£¬£¬¼õÇáѪ¹Ü¸Æ»¯¡£¡£ÕâÒ»Ö÷Òª·¢Ã÷²»µ«Ú¹ÊÍÁËÀ±½·ÉãÈë½µµÍÐÄѪ¹Ü¼²²¡éæÃü·çÏÕµÄDZÔÚ»úÀí£¬£¬Ò²ÎªÑª¹Ü¸Æ»¯ÌṩÁËеÄÖÎÁưе㼰ÖÎÁÆÀíÄî¡£¡£
¸ÃÊÂÇéÓÉngµç×ÓÓÎϷΪ×ÔÁ¦Íê³Éµ¥Î»£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚ°ËÒ½Ôº²©Ê¿ÉúÂÞ¶¬ÁáºÍÀèÎÄÐÅΪ²¢ÁеÚÒ»×÷Õߣ¬£¬ÂÛÎÄ×ÔÁ¦Í¨Ñ¶×÷Õ߻ƻԽÌÊÚ¶àÄêÀ´Ò»Ö±ÖÂÁ¦ÓÚѪ¹Ü¸Æ»¯¡¢¡¢Ñª¹ÜÐàÂõµÄÑо¿£¬£¬×¢ÖØ»ù´¡ÓëÁÙ´²µÄת»¯Ó¦Óᣡ£ÔÚ¸ßѪѹ£¬£¬ÐÄÉö¶Ô»°ÐÂǰÑÔ£¬£¬Ñ×ÐÔÐàÂõºÍ±í¹ÛÒÅ´«Ñ§·½Ã棬£¬Ì½Ë÷¶¯Âö¸Æ»¯±¬·¢ÆøÖƺÍÁÙ´²×ª»¯£¬£¬È¡µÃϵÁÐÁ¢ÒìÐÔЧ¹û£¬£¬ÔÚ¸ÃÁìÓòÒѾ½ÒÏþÏà¹ØÑо¿Ð§¹û£¬£¬°üÀ¨J Clin Invest£¨2021£¬£¬2022£©¡¢¡¢Hypertension£¨2018£¬£¬2021£¬£¬2022£©¡¢¡¢Signal Transduct Target Ther¡¢¡¢Cell Death Differ¡¢¡¢TheranosticsºÍATVBµÈרҵÆÚ¿¯¡£¡£
ÂÛÎÄÁ´½Ó: https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.121.18778